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Thiazolidinediones and Advanced Liver Fibrosis
in Nonalcoholic Steatohepatitis
AMeta-analysis
Giovanni Musso, MD; Maurizio Cassader, PhD; Elena Paschetta, MD; Roberto Gambino, PhD
IMPORTANCE Nonalcoholic steatohepatitis (NASH) is projected to be the leading cause of
liver transplantation by 2020. Advanced fibrosis (stage F3-F4) on liver biopsy independently
predicts all-cause and liver-relatedmortality in NASH. There are no known efficacious
treatments for advanced fibrosis related to NASH. Thiazolidinedione therapy has been
extensively evaluated in NASH, and new randomized clinical trials (RCTs) of its efficacy have
been completed.
OBJECTIVE To synthesize the evidence about the association of thiazolidinedione therapy
with advanced liver fibrosis in NASH.
DATA SOURCES MEDLINE, OvidMEDLINE In-Process, Cochrane Library, EMBASE,
clinicaltrials.gov, PubMed, and Scopus databases (without language restrictions), as well as
other registries and scientific meeting presentations, from database inception through
August 15, 2016.
STUDY SELECTION Randomized clinical trials evaluating the effect of thiazolidinedione
therapy on histologic features of the liver in biopsy-proven NASH.
DATA EXTRACTION AND SYNTHESIS Two investigators extracted study data independently and
in duplicate and rated the risk of bias using the Cochrane Risk of Bias Tool.
MAIN OUTCOMES ANDMEASURES The primary outcomewas a dichotomous improvement in
advanced fibrosis on liver biopsy, defined as an improvement in fibrosis stage from F3-F4 to
F0-F2. Secondary outcomes were at least a 1-point improvement in fibrosis of any stage and
NASH resolution. This meta-analysis also evaluated adverse effects of thiazolidinedione
therapy, including weight gain, lower limb edema, congestive heart failure, bone fractures,
cancer, and anemia. With the use of random-effects models, dichotomous variables are
presented as odds ratios (ORs) with 95% CIs, and continuous variables are presented as
weightedmean differences with 95% CIs.
RESULTS This study analyzed 8 RCTs (5 evaluating pioglitazone use and 3 evaluating
rosiglitazonemaleate use) enrolling 516 patients with biopsy-proven NASH for a duration of 6
to 24months. Among all studies combined, thiazolidinedione therapy was associated with
improved advanced fibrosis (OR, 3.15; 95% CI, 1.25-7.93; P = .01; I2 = 0%), fibrosis of any
stage (OR, 1.66; 95% CI, 1.12-2.47; P = .01; I2 = 0%), and NASH resolution (OR, 3.22; 95% CI,
2.17-4.79; P < .001; I2 = 0%). Analyses restricted to RCTs enrolling patients without diabetes
yielded similar results for improvement in advanced fibrosis (OR, 2.95; 95% CI, 1.04-10.90;
P = .02; I2 = 0%), improvement in fibrosis of any stage (OR, 1.76; 95% CI, 1.02-3.03; P = .02;
I2 = 0%), and NASH resolution (OR, 3.40; 95% CI, 1.95-5.93; P < .001; I2 = 0%). All effects
were accounted for by pioglitazone use. Weight gain and lower limb edema occurredmore
frequently with thiazolidinedione therapy (initial body weight +2.70%; 95% CI, 1.96%-4.34%;
P = .001). The small sample size of included RCTs prevented evaluation of more serious
adverse effects of thiazolidinedione therapy.
CONCLUSIONS AND RELEVANCE Pioglitazone use improves advanced fibrosis in NASH, even in
patients without diabetes. Whether this finding translates to improvement in risk for clinical
outcomes requires further study.
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N onalcoholic fatty liver disease (NAFLD) is the mostcommon chronic liver disease in the world, encom-passing a histological spectrum ranging from simple
steatosis to steatosis plus necroinflammation, known as non-
alcoholic steatohepatitis (NASH),withvariable stagesof fibro-
sis. Both fibrosis stage andNASHcanonly be assessedby liver
biopsy.1
There is no established treatment for NASH, which is the
second leading cause of liver disease among adults awaiting
liver transplant and is projected by 2020 to be the leading in-
dication for liver transplant.2,3Extensiveexperimental andepi-
demiological evidence suggests that the presence of ad-
vanced fibrosis (stageF3-F4) (ie, bridging fibrosis or cirrhosis)
on liver biopsy is the only independent predictor of poor out-
comes inNAFLD;overall and liver-relatedmortality, liver trans-
plant, and liver-related complications are increased in ad-
vanced fibrosisbutnot inpatientswithNASHormilder fibrosis
(stage F0-F2), whose prognosis is similar to that of the gen-
eralpopulation.4,5Recentguidelineshighlight theneedto iden-
tifypatientswithNAFLDwithadvanced fibrosis to target them
formore intensivemonitoring for theonsetof complications.6,7
However, although reversal of advanced fibrosishasbeengen-
erally associated with improved clinical outcomes in other
causes of chronic liver disease,8,9 this stage of diseasewasnot
improved by any of the treatments evaluated to date in ran-
domized clinical trials (RCTs) of NASH.10,11
The thiazolidinedione antidiabetic agents have been ex-
tensivelyevaluated inNASH.While access to rosiglitazonema-
leate has been restrictedby theUSFoodandDrugAdministra-
tion,pioglitazonehydrochloridecontinues toberecommended
in current diabetes guidelines, and novel data evaluating this
drug inNASHhave been recently published.12 The results of a
previous meta-analysis10 suggested that thiazolidinedione
therapy improved histological features of NASH but not ad-
vanced fibrosis. Therefore, we analyzed the evidence on thia-
zolidinedione therapy inNASH, focusing on their effect in ad-
vanced fibrosis.
Methods
Data Sources and Searches
The study protocol was approved by the Humanitas Grad-
enigoReviewBoard.We searchedEnglish-language andnon–
English-language publications in MEDLINE, Ovid MEDLINE
In-Process, Cochrane Library, EMBASE, clinicaltrials.gov,
PubMed, and Scopus databases from database inception
throughAugust 15, 2016.Wealso reviewed abstracts froman-
nual meetings of the American Association for the Study of
LiverDisease, AmericanGastroenterological Association, Eu-
ropean Association for the Study of Liver, American Diabetes
Association, European Association for the Study of Diabetes,
andDigestiveDiseaseWeek.All included referenceswere sub-
jected to the same quality assessment.
Search terms were nonalcoholic steatohepatitis (NASH),
nonalcoholic fatty liver disease (NAFLD), fatty liver, liver fat,
steatosis, liver enzymes, transaminase,alanine aminotransfer-
ase (ALT),aspartate aminotransferase (AST), γ-glutamyl trans-
ferase (GGT), severity of liver disease, fibrosis, advanced fibro-
sis, fibrosis stageF3, fibrosis stageF4,bridging fibrosis, cirrhosis,
treatment, therapy, efficacy, trial, thiazolidinedione, rosiglita-
zone,pioglitazone, troglitazone, glitazone, andperoxisomepro-
liferator–activated receptor γ agonist (PPAR-γ agonist). An ex-
ample of the full electronic search strategy is included in the
eMethods in the Supplement.
Study Selection
Inclusion criteria were English-language and non–English
-language articles reportingRCTs enrollingparticipants of any
sex or racial/ethnic origin with NAFLD or NASH, diagnosed
on the basis of radiological or histological evidence of steato-
sis according to accepted criteria.1 Relevant meta-analyses
were also included if they followed the Preferred Reporting
Items for Systematic Reviews and Meta-analyses (PRISMA)
guidelines.13
Excluded from the meta-analysis were nonhuman stud-
ies, nonrandomized trials, letters, and case reports. Also ex-
cluded were studies enrolling fewer than 10 participants, ar-
ticles not reporting outcomes of interest or primary data
(editorials and reviewarticles), and investigationsusing inad-
equate case definitions or enrolling patients with secondary
steatosis (eg, drug-induced steatosis and total parenteral nu-
trition–induced steatosis).
Data Extraction andQuality Assessment
Datawere extracted fromeach studyby2ofus (G.M. andM.C.)
independently and in duplicate. Agreement between the 2 re-
viewersonstudyselectionandqualityassessmentofstudieswas
evaluatedbyκstatistics,anddisagreementwasresolvedbymu-
tual discussion. Authorswere contacted to obtain further data
and toverifymethodological quality.Datawere thenextracted
fromeachstudy independentlyand induplicateby2ofus (G.M.
andR.G.)usingapredefinedprotocolandadataextractionsheet.
Discrepancieswereresolvedbymutualdiscussion.Methodologi-
calqualityofRCTswasassessedusingeachitemspecifiedbythe
CochraneRiskofBiasTool (score range,0-8)14 (Table).Random-
izedclinical trials scoringhigher than6werearbitrarily consid-
eredashavinga lowriskofbias. Theanalysiswasperformed in
Key Points
Question What is the association of thiazolidinedione therapy
with advanced liver fibrosis in nonalcoholic steatohepatitis?
Findings In this meta-analysis of 8 randomized clinical trials
enrolling 516 patients with biopsy-proven nonalcoholic
steatohepatitis, thiazolidinedione therapy was associated with
reversed advanced fibrosis, improved overall fibrosis stages, and
resolution of nonalcoholic steatohepatitis. Pioglitazone
hydrochloride use accounted for all of the effects of
thiazolidinedione therapy in nonalcoholic steatohepatitis, and
these benefits were observed in patients without diabetes as well.
Meaning Pioglitazone use improves advanced fibrosis in
nonalcoholic steatohepatitis, even in patients without diabetes,
andmay thus halt disease progression to end-stage liver disease in
this patient population.
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accord with the Cochrane Handbook for Systematic Reviews of
Interventions14usingastatisticalsoftwareprogram(RevMan,ver-
sion5.3.5;TheCochraneCollaboration), anddatawerereported
according to PRISMAguidelines.13
Data Synthesis and Analysis
The primary outcome variable was a dichotomous improve-
ment in advanced fibrosis (stage F3-F4) on liver biopsy, de-
fined as a 2-point improvement in fibrosis stage from F3-F4
toF0-F2on theNASHClinicalResearchNetworkScale.An im-
provement in advanced fibrosis was defined in the following
2ways: (1) the number of individuals among all patients with
NASH included in the RCT whose fibrosis stage had changed
fromF3-F4 to F0-F2 at the end of treatment and (2) the num-
ber of individuals among patients with NASHwith advanced
fibrosis (stage F3-F4) at baseline whose fibrosis stage had
changed from F3-F4 to F0-F2 at the end of treatment.
Secondary dichotomous outcome variables were at least
a 1-point improvement in fibrosis of any stage on the NASH
Clinical Research Network Scale in patients with NASH and
NASH resolution, with fibrosis stage and NASH defined ac-
cording to current guidelines.1 We also evaluated adverse ef-
fectsof thiazolidinedione therapy, includingweightgain, lower
limb edema, congestive heart failure, bone fractures, cancer,
and anemia.
Dichotomous variables are presented as odds ratios (ORs)
with95%CIs,andcontinuousvariablesarepresentedasweighted
meandifferenceswith95%CIs.Weconservativelyusedrandom-
effectsmodels,withsignificancesetatP = .05.Statisticalhetero-
geneity was assessed with the I2 statistic. Using I2 of 50% or
higher, we planned to explore individual study characteristics
and those of subgroups in themain body of evidence.
Sensitivity analysiswasperformedby removing 1 studyat
a time and repeating themeta-analysis to assesswhether any
single study substantially affected pooled estimates. In addi-
tion, we planned a priori subgroup analysis according to the
following criteria: RCTs evaluating rosiglitazone use vs RCTs
evaluating pioglitazone use, RCTs enrolling exclusively pa-
tientswithoutdiabetesvsRCTsalsoenrollingpatientswithdia-
betes, and treatment duration of 1 year or less vs longer than 1
year and different dosages, as well as for each item of the
Cochrane Risk of Bias Tool.
When at least 8 comparisons were available, the effect of
age, changes in insulin resistance (as estimatedby thehomeo-
stasismodel of insulin resistance index), and treatment dura-
tion on assessed outcomeswas evaluated bymeta-regression
analysis (using random-effectsmodels,withwithin-studyvari-
ance estimated with the unrestricted maximum likelihood
method).Publicationbiaswasexaminedusing funnelplotsand
the Egger test.
Management ofMissing Data
Missing data weremanaged by contacting the corresponding
authors of theRCTs. If this contactwas unsuccessful,missing
Table. Randomized Clinical Trials (RCTs)With Posttreatment Histological Features of the Liver Assessing Thiazolidinedione Therapy
in Nonalcoholic Steatohepatitis (NASH) Included in theMeta-analysis
Source
No. of
Patients
Mean
Age, y
Male,
%
Mean
BMI
Diabetes,
%
Agent
(Daily Dosage)
Trial
Duration, mo Comparator
BMI
Change From
Baseline, %
Quality
Scorea
Ratziu
et al,15
2008
63 54 59 31 31 Rosiglitazone
maleate (8 mg)
12 Placebo +1 7 (H)
Sanyal
et al,16
2004
20 46 50 32 0 Pioglitazone
hydrochloride
(30 mg)
6 Vitamin E 0 7 (E)
Belfort
et al,17
2006
55 51 45 34 48 Pioglitazone
hydrochloride
(45 mg)
6 Placebo +2.7 7 (E)
Aithal
et al,18
2008
74 54 61 31 0 Pioglitazone
hydrochloride
(30 mg)
12 Placebo +3 7 (E)
Idilman
et al,19
2008
74 47 59 32 0 Rosiglitazone
maleate (8 mg)
12 Metformin
hydrochloride,
placebo
−2.6 4 (B, C, D, E)
Omer
et al,20
2010
64 49 55 31 70 Rosiglitazone
maleate (4 mg)
12 Metformin
hydrochloride,
metformin
hydrochloride
plus
rosiglitazone
maleate
0 4 (B, C, D, E)
Sanyal
et al,21
2010
247 46 40 34 0 Pioglitazone
hydrochloride
(30 mg)
24 Vitamin E,
placebo
+4.8 8
Cusi
et al,12
2016
101 51 70 34 51 Pioglitazone
hydrochloride
(45 mg)
18 Placebo +1 8
Abbreviation: BMI, bodymass index (calculated as weight in kilograms divided
by height in meters squared).
a The Cochrane Risk of Bias Tool (score range, 0-8) score for RCTs is reported,
with failing items in parentheses. Quality items of RCTs according to the
Cochrane Risk of Bias Tool are as follows: A (adequate method of sequence
generation), B (masking of participants performed), C (masking of personnel
performed), D (masking of assessors performed), E (randomization
concealment adequate), F (adequate assessment of each outcome),
G (selective outcome reporting avoided), and H (intent-to-treat analysis of the
results).
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histological scoreswerecalculated fromtherawnumbersgiven
in tables or estimated from bar charts. For missing SDs of the
mean change in scores and where the P value was provided
for a comparison between treated and control groups, the SD
was calculated by converting the P value to a t statistic with
appropriatedf and then calculating SEs andSDs. If neither the
SD nor the P values were supplied, imputation of an SD from
studieswithsimilarmeasurementmethods, trialduration, and
measurement error was used if available, tested in a sensitiv-
ity analysis, and reported if the estimate differed meaning-
fully from previous estimates.
Results
The agreement between reviewerswas good to excellent. The
κ statistics were 0.88 for study selection and 0.92 for quality
assessment.
A flow diagram of study selection is shown in Figure 1.
We identified 8 RCTs (5 evaluating pioglitazone use and 3
evaluating rosiglitazone use, with posttreatment histological
features of the liver) enrolling 516 patients. Trial durations
were 6 to 24 months, with daily dosages ranging from 4 to 8
mg for rosiglitazone maleate and from 30 to 45 mg for piogli-
tazone hydrochloride (Table).12,15-21 For the included RCTs,
the histopathological scoring system proposed by the NASH
Clinical Research Network was used to score the severity of
histological features of the liver, as recommended by current
guidelines.1,6,7 Fibrosis was assessed by Masson trichrome
stain, and the pathologist intraobserver and interobserver
agreement for fibrosis staging was good to excellent (κ statis-
tic, ≥0.82).
The agreement between reviewers for quality assess-
mentwasgood (κ statistic,0.84).Overall, 6RCTshada lowrisk
of bias in key domains, while 2 RCTs (both evaluating rosi-
glitazone use) demonstrated a higher risk of bias because of
unclear blinding and randomization concealment.19,20
Pooled results of RCTs showed that thiazolidinedione
therapy was associated with improved advanced fibrosis
(Figure 2). The effect sizewas significantwhenconsidering all
patients with NASH (Figure 2A) and only patients with NASH
withadvanced fibrosisatbaseline (Figure2B). Inaddition, thia-
zolidinedione therapywas associatedwith improved fibrosis
of any stage and induced NASH resolution (Figure 3). Statis-
tical heterogeneity was low for all evaluated outcomes, sug-
gesting a consistent effect size across studies.
After the analysis to RCTs enrolling exclusively to
patients without diabetes was restricted, pooled ORs
remained similar in magnitude and direction to the overall
effect. Among the 4 studies, thiazolidinedione therapy was
associated with improvement in advanced fibrosis (OR, 2.95;
95% CI, 1.04-10.90; P = .02; I2 = 0%), improvement in fibro-
sis of any stage (OR, 1.76; 95% CI, 1.02-3.03; P = .02;
I2 = 0%), and NASH resolution (OR, 3.40; 95% CI, 1.95-5.93;
P < .001; I2 = 0%).
Trialduration,dosage,andexclusionof the2RCTs16,18with
a high risk of bias (both evaluating rosiglitazone use) did not
affect themagnitude anddirectionof the overall effect.Meta-
regressionanalysis foundnoassociationbetweenassessedout-
comes and age, homeostasis model of insulin resistance in-
dex, and treatment duration.
The separate analyses of rosiglitazone and pioglitazone
demonstrated that the observed effects of thiazolidinedione
therapy were accounted for by pioglitazone use. Rosiglita-
zone use did not reach statistical significance for any histo-
logical outcome (Figure 2).
TheEgger testandfunnelplotanalysis foundnostrongevi-
dence for publication bias. These results are shown in eFig-
ure 1 in the Supplement.
Thiazolidinedione therapy was associated with a mean
2.7% weight gain compared with controls (eFigure 2 in the
Supplement). Itwas also associatedwith ahigherOR for lower
limbedema (2.36; 95%CI, 1.15-4.84;P = .02; I2 = 0%) (6 stud-
ies),without any significantdifference in agents,RCTs, or trial
duration.
Reporting of other adverse events was variable. Recog-
nized adverse effects, such as congestive heart failure, were
reported in fewer than half of the RCTs.
Figure 1. Evidence Acquisition FlowDiagram
12 337 Excluded by specific criteria
Nonhuman studies
Letters or case reports
Did not report outcome of interest
Did not report primary data
(editorials, reviews)
Pediatric population only
Inadequate case definition
<10 Patients included
200 RCTs excluded
21 Inadequate case definition
106 Not assessing treatment of interest
64 Nonrandomized trials
13 Controlled nonrandomized
51 Uncontrolled
4 Retrospective studies
5 Meta-analyses
8 RCTs without posttreatment histological
features of the liver excluded
12 553 Publications identified
16 RCTs assessing thiazolidinediones
therapy in NAFLD
8 RCTs with posttreatment histological
features of the liver assessing
thiazolidinediones therapy in NASH
included
216 Unique publications meeting
inclusion criteria
143 RCTs
13 Controlled nonrandomized
trials
51 Uncontrolled trials
4 Retrospective studies
5 Meta-analyses
NAFLD indicates nonalcoholic fatty liver disease; NASH, nonalcoholic
steatohepatitis; and RCTs, randomized clinical trials.
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Discussion
In this meta-analysis of 8 RCTs of thiazolidinedione therapy,
we found that treatment for up to 24 months was associated
with improved advanced fibrosis and fibrosis of any stage and
NASH resolution. These effectsweremainly accounted for by
pioglitazoneuse. Benefitswere also observed inpatientswith
NASHwithoutdiabetes.Aside fromweightgainand lower limb
edema,nomajor adverse eventswere reportedduring the trial
durations, with recognizable power limitations of our analy-
sis because of the few included RCTs.
Figure 2. Thiazolidinedione Therapy (TZD) and Improvement in Advanced Fibrosis, Improved Fibrosis of Any Stage, and Nonalcoholic Steatohepatitis
(NASH) Resolution
All patients with NASHA
Weight, %
Favors
Controls
Favors
TZD
0.01 101.0 1000.1
OR (95% CI)
TZD
No. of
Events
No. of
Patients
Control
No. of
Events
No. of
PatientsSource
Rosiglitazone maleate
Odds Ratio (95% CI)
7.71 11 0 8Idilman et al,19 2008 2.43 (0.09-67.57)
10.51 20 1 22Omer et al,21 2010 1.11 (0.06-18.93)
10.71 32 1 31Ratziu et al,18 2008 0.97 (0.06-16.19)
Heterogeneity: τ2 = 0.00; χ22 = 0.19; P = .91; I2 = 0%
Overall effect: z = 0.30; P = .77
29.03 63 2 61Total (95% CI) 1.30 (0.23-7.20)
Pioglitazone hydrochloride
9.43 31 0 30Aithal et al,17 2008 7.49 (0.37-151.50)
9.97 26 0 21Belfort et al,16 2006 16.54 (0.89-308.98)
9.84 50 0 51Cusi et al,12 2016 9.97 (0.52-190.16)
10.01 10 1 10Sanyal et al,15 2004 1.00 (0.05-18.57)
32.06 80 2 83Sanyal et al,20 2010 3.28 (0.64-16.78)
Heterogeneity: τ2 = 0.00; χ22 = 2.39; P = .66; I2 = 0%
Overall effect: z = 2.71; P = .007
71.021 197 3 195Total (95% CI) 4.53 (1.52-13.52)
Heterogeneity: τ2 = 0.00; χ22 = 4.12; P = .77; I2 = 0%
Overall effect: z = 2.44; P = .01
10024 260 5 256Total (95% CI) 3.15 (1.25-7.93)
Patients with NASH with advanced fibrosis at baselineB
Weight, %
Favors
Controls
Favors
TZD
0.01 101.0 1000.1
OR (95% CI)
TZD
No. of
Events
No. of
Patients
Control
No. of
Events
No. of
PatientsSource
Rosiglitazone maleate
Odds Ratio (95% CI)
8.61 3 0 3Idilman et al,19 2008 4.20 (0.12-151.97)
11.51 7 1 4Omer et al,21 2010 0.50 (0.02-11.09)
12.41 5 1 15Ratziu et al,18 2008 3.50 (0.18-69.34)
Heterogeneity: τ2 = 0.00; χ22 = 1.06; P = .59; I2 = 0%
Overall effect: z = 0.65; P = .52
32.53 15 2 22Total (95% CI) 1.84 (0.29-11.66)
Pioglitazone hydrochloride
11.13 7 0 11Aithal et al,17 2008 17.89 (0.76-420.49)
6.37 7 0 2Belfort et al,16 2006 75.00 (1.16-4868.64)
10.74 7 0 5Cusi et al,12 2016 14.14 (0.57-352.00)
7.21 2 1 2Sanyal et al,15 2004 1.00 (0.02-50.40)
32.26 12 2 19Sanyal et al,20 2010 8.50 (1.33-54.13)
Heterogeneity: τ2 = 0.00; χ22 = 2.43; P = .66; I2 = 0%
Overall effect: z = 3.55; P <.001
67.521 35 3 39Total (95% CI) 10.17 (2.83-36.54)
Heterogeneity: τ2 = 0.00; χ22 = 5.71; P = .57; I2 = 0%
Overall effect: z = 3.29; P = .001
10024 50 5 61Total (95% CI) 5.84 (2.04-16.71)
A, Improvement in advanced fibrosis (stage F3-F4) in patients with
biopsy-proven NASH, defined as the number of patients with NASHwhose
fibrosis stage had changed from F3-F4 to F0-F2 at the end of treatment.
B, Improvement in advanced fibrosis (stage F3-F4) in patients with NASHwith
advanced fibrosis, defined as the number of patients with NASHwith advanced
(F3-F4) fibrosis at baseline whose fibrosis stage had changed from F3-F4 to
F0-F2 at the end of treatment. In contrast to A, only patients with NASH and
advanced fibrosis were included as the denominator in B.
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Nonalcoholic steatohepatitis is becoming a major public
health issue and is a leading cause of liver transplant.2,3,6,7,22
Among the clinical andhistological features ofNAFLD, the se-
verity of liver fibrosis hasbeenmechanistically andepidemio-
logically linked to increased overall and liver-related mortal-
ity and liver-related complications. Specifically, advanced
fibrosis (stageF3-F4) (ie, bridging fibrosis or cirrhosis) on liver
biopsy is the strongest independent predictor of poor out-
comes in NAFLD and NASH and has been recognized in re-
cent guidelines as themain diagnostic and therapeutic target
tohaltNASHprogression toend-stage liverdisease, change the
natural history of the disease, and improve long-term prog-
nosisofpatientswithNASH.4-7,23,24Unfortunately,noneof the
pharmacological agentsevaluated inpriorphase 1, 2, and3 ran-
domized trials showed improvement of advanced fibrosis in
patients with NASH.10,11
We found that thiazolidinedione therapy (specifically
pioglitazone use) for up to 24 months was associated with a
Figure 3. Improved Fibrosis of Any Stage and Nonalcoholic Steatohepatitis (NASH) Resolution
Improvement in fibrosis of any stageA
Weight, %
Favors
Controls
Favors
TZD
101.00.1
OR (95% CI)
TZD
No. of
Events
No. of
Patients
Controls
No. of
Events
No. of
PatientsSource
Rosiglitazone maleate
Odds Ratio (95% CI)
1.62 11 0 8Idilman et al,19 2008 4.47 (0.19-106.96)
5.23 20 3 22Omer et al,21 2010 1.12 (0.20-6.30)
8.65 32 5 31Ratziu et al,18 2008 0.96 (0.25-3.72)
Heterogeneity: τ2 = 0.00; χ22 = 0.78; P = .68; I2 = 0%
Overall effect: z = 0.33; P = .74
15.410 63 8 61Total (95% CI) 1.18 (0.43-3.25)
Pioglitazone hydrochloride
11.29 31 6 30Aithal et al,17 2008 1.64 (0.50--5.35)
11.112 26 7 21Belfort et al,16 2006 1.71 (0.52-5.64)
21.920 50 13 51Cusi et al,12 2016 1.95 (0.84-4.54)
2.32 10 1 10Sanyal et al,15 2004 2.25 (0.17-29.77)
38.235 80 26 83Sanyal et al,20 2010 1.71 (0.90-3.24)
Heterogeneity: τ2 = 0.00; χ22 = .12; P > .99; I2 = 0%
Overall effect: z = 2.60; P = .009
84.678 197 53 195Total (95% CI) 1.77 (1.15-2.72)
Heterogeneity: τ2 = 0.00; χ22 = 1.40; P >.99; I2 = 0%
Overall effect: z = 2.52; P = .01
10088 260 61 256Total (95% CI) 1.66 (1.12-2.47)
Induction of NASH resolutionB
Weight, %
Favors
Controls
Favors
TZD
101.0 200.1
OR (95% CI)
TZD
No. of
Events
No. of
Patients
Controls
No. of
Events
No. of
PatientsSource
Rosiglitazone maleate
Odds Ratio (95% CI)
1.74 11 0 8Idilman et al,19 2008 10.20 (0.47-222.45)
6.35 20 3 22Omer et al,21 2010 2.11 (0.43-10.28)
15.416 32 11 31Ratziu et al,18 2008 1.82 (0.66-5.00)
Heterogeneity: τ2 = 0.00; χ22 = 1.11; P = .58; I2 = 0%
Overall effect: z = 1.82; P = .07
23.325 63 14 61Total (95% CI) 2.14 (0.94-4.86)
Pioglitazone hydrochloride
13.614 31 8 30Aithal et al,17 2008 2.26 (0.77-6.63)
7.511 26 3 21Belfort et al,16 2006 4.40 (1.03-18.74)
20.026 50 10 51Cusi et al,12 2016 4.44 (1.83-10.78)
2.75 10 1 10Sanyal et al,15 2004 9.00 (0.81-100.14)
32.938 80 17 83Sanyal et al,20 2010 3.51 (1.76-7.01)
Heterogeneity: τ2 = 0.00; χ22 = 1.56; P = .82; I2 = 0%
Overall effect: z = 5.61; P < .001
76.794 197 39 195Total (95% CI) 3.65 (2.32-5.74)
Heterogeneity: τ2 = 0.00; χ22 = 3.90; P = .79; I2 = 0%
Overall effect: z = 5.79; P < .001
100119 260 53 256Total (95% CI) 3.22 (2.17-4.79)
A, Improvement by at least 1 stage in liver fibrosis of any stage in patients with
biopsy-proven NASH. B, Effects of thiazolidinedione therapy on NASH
resolution, defined as the number of patients with NASHwho showed NASH
resolution at the end of treatment. OR indicates odds ratio.
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reversal of advanced fibrosis stage in NASH and may thus
improve long-term prognosis in this subgroup of patients
who are at higher risk of poor liver-related outcomes.4-7
These benefits were also observed in patients without diabe-
tes, which may prompt the extension of approved indica-
tions for pioglitazone use.
It is unclear why pioglitazone use (and not rosiglitazone
use) accounted for all of the benefits observed with thiazoli-
dinedione therapy in our analysis, indicating that this obser-
vation may not be a class effect of these drugs. Possible dif-
ferences can be explained by the differential effects of
pioglitazone and rosiglitazone on inflammation and fibrosis
mechanisms, such as through up-regulation of adiponectin,
activationof adenosinemonophosphate–activatedproteinki-
nase, and induction of hepatic stellate cell senescence.25,26
Thebenefitsofpioglitazoneuseshouldbeweighedagainst
its adverseeffects,which inouranalysiswere limited toweight
gain and lower limb edema. The short trial durations (≤24
months) and few included RCTs may have limited the power
of our analysis to detect more serious adverse effects of thia-
zolidinedione therapy. Therefore, careful tailoring of indi-
vidual risk-benefit profiles will be essential to limit exposure
to adverse effects of pioglitazone use. The restriction of pio-
glitazoneuse to thosepatientswithadvanced liver fibrosis and
a higher risk of liver-related death seems plausible. Two pa-
tients with NASHwith advanced fibrosis would be needed to
take pioglitazone to improve advanced fibrosis in 1 patient
(number needed to treat, 1.9).
Limiting the duration of pioglitazone use may also
reduce exposure to adverse effects. Within this context, 2
trials12,27 suggest that theuseof thiazolidinedione therapybe-
yond 18 months does not offer significant additional histo-
logical benefit. Finally, a key issue after pioglitazone discon-
tinuation is the prevention of liver disease recurrence. Other
study28 results suggest that the durability of histological re-
sponse obtained with thiazolidinedione therapy depends on
theachievementof sustained lifestyle changes,particularly in-
creased physical activity.
Limitations
Limitationsofourmeta-analysis,whichare inherent to thena-
ture of the included studies, need to bementioned. Included
RCTs had small sample sizes and evaluated the effect of thia-
zolidinedionetherapyonhistological featuresof the liver rather
thanonclinical outcomes.However, as acknowledgedby con-
sensus of theAmericanAssociation for the Studyof LiverDis-
eases and theUSFood andDrugAdministration,29 because of
the slow progressive nature of NASH it is impractical and un-
feasible to perform larger studies of long duration to identify
treatment-related clinical benefits, and histological features
of the liver offer thebest surrogatemeasureof the riskof liver-
related complications. Among all histological features of
NAFLD, advanced liver fibrosis has beenmechanistically and
epidemiologically linked to an increased risk of adverse liver-
related complications in NAFLD, and reversal of advanced fi-
brosis portends an improved prognosis in diverse causes of
chronic liver disease.8,9,11
Conclusions
Recent guidelines recommend identification of patients with
NAFLDwith advanced fibrosis to target them formore inten-
sive monitoring of the onset of complications but acknowl-
edge the lack of therapeutic options that effectively reverse
advanced stages of liver disease.1,6,7 The new finding in this
meta-analysis is that treatmentwith theantidiabetic drugpio-
glitazone reverses the more advanced stages of liver disease
in NASH regardless of the presence of diabetes, which pro-
vides a rationale for evaluating the effect of this drug on clini-
cal outcomes in this subgroupofpatients athigher riskof liver-
related complications.
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Invited Commentary
The Role of Pioglitazone in theManagement
of Nonalcoholic Steatohepatitis
AreWe There Yet?
Hal F. Yee Jr, MD, PhD
Nonalcoholic steatohepatitis (NASH) and its clinical
sequelae have become an increasingly prevalent and impor-
tant cause of hepatic morbidity and mortality.1 Despite
almost 2 decades of intense study, we are still not certain
how best to treat NASH. In this issue of JAMA Internal Medi-
cine, Musso and colleagues present a meta-analysis that
suggests that thizaolidinedione use is associatyed with
improvement in advanced
fibrosis in NASH, even in
patients without diabetes.2
Other medications in the
thiazolidinedione class did not demonstrate a significant
effect in treatment of nonalcoholic steatohepatitis, there-
fore this commentary focuses on pioglitazone. Although
this article makes a significant contribution to our under-
standing of the potential role that this thiazolidinedione
may have in the management of NASH, there remain sub-
stantive questions that need to be addressed before pioglita-
zone hydrochloride can be recommended as a treatment for
patients with NASH.
Does pioglitazone alter clinical outcomes, such as devel-
opmentof ascites or encephalopathy, need for liver transplan-
tation,or liver-relateddeath?Thismeta-analysis identifiedsig-
nificant improvements in histological features of the liver in
patients treatedwith pioglitazone, but it did not look at clini-
cal outcomes. Although liver histological status is a com-
monly used surrogate outcome in evaluating the efficacy of
treatments for other hepatic conditions, it might not corre-
late aswellwith clinical outcomes inpatientswithNASH,who
are often obese and have type 2 diabetes and other complica-
tions ofmetabolic syndrome. Suchpatients are at high risk for
serious cardiovascular and neurovascular complications (ie,
myocardial infarction or stroke), which could influence clini-
cal outcome more strongly than the complications of NASH.
Further longitudinal studies will be required to determine if
pioglitazone improves clinical outcomes.
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